Shares of Fresenius Medical Care AG (NYSE:FMS) saw strong trading volume on Thursday . 257,391 shares changed hands during mid-day trading, an increase of 62% from the previous session’s volume of 158,433 shares.The stock last traded at $46.31 and had previously closed at $46.20.

Several equities research analysts have recently weighed in on the company. Berenberg Bank reiterated a “buy” rating on shares of Fresenius Medical Care AG in a research note on Tuesday, August 9th. DZ Bank AG reiterated a “neutral” rating on shares of Fresenius Medical Care AG in a research note on Thursday, August 4th. Jefferies Group upgraded Fresenius Medical Care AG from an “underperform” rating to a “hold” rating in a research note on Friday, July 8th. Zacks Investment Research raised Fresenius Medical Care AG from a “sell” rating to a “hold” rating in a report on Wednesday, May 4th. Finally, Royal Bank Of Canada reissued a “hold” rating on shares of Fresenius Medical Care AG in a report on Tuesday, May 24th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $42.50.

The stock has a market cap of $28.39 billion and a PE ratio of 25.73. The stock has a 50-day moving average of $45.02 and a 200-day moving average of $43.44.

Fresenius Medical Care AG (NYSE:FMS) last announced its earnings results on Tuesday, August 2nd. The company reported $0.96 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.92 by $0.04. The business had revenue of $4.42 billion for the quarter, compared to the consensus estimate of $4.54 billion. On average, analysts expect that Fresenius Medical Care AG will post $2.01 earnings per share for the current year.

A number of hedge funds and institutional investors have recently made changes to their positions in the stock. Comerica Bank boosted its position in shares of Fresenius Medical Care AG by 5.4% in the fourth quarter. Comerica Bank now owns 35,387 shares of the company’s stock worth $1,486,000 after buying an additional 1,798 shares during the period. Bank of Montreal Can boosted its position in shares of Fresenius Medical Care AG by 60.0% in the fourth quarter. Bank of Montreal Can now owns 56,700 shares of the company’s stock worth $2,373,000 after buying an additional 21,264 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Fresenius Medical Care AG by 3.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 107,376 shares of the company’s stock worth $4,493,000 after buying an additional 3,694 shares during the period. Finally, Morgan Stanley boosted its position in shares of Fresenius Medical Care AG by 20.5% in the fourth quarter. Morgan Stanley now owns 685,338 shares of the company’s stock worth $28,675,000 after buying an additional 116,653 shares during the period.

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.